Clinical and angiographic follow-up after coronary drug-eluting and bare metal stent implantation. Do drug-eluting stents hold the promise?

Journal of Internal Medicine

Volumn 260, Issue 2, 2006, Pages 118-124

  Jensen, J ^a   Lagerqvist, B ^a   Aasa, M ^b   Sarev T ^a   Nilsson, T ^c   Tornvall, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angioplasty; Restenosis; Revascularization; Stent

Indexed keywords

RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DIABETES MELLITUS; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SWEDEN; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 33745918638     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01669.x     Document Type: Article

References (20)

1. Hoffman R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of instent restenosis: a serial intravascular ultrasound study. Circulation 1996; 94: 1247-54.
2. Kastrati A, Schomig A, Elezi S et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428-36.
3. Bauters C, Hubert E. Prat A et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31: 1291-8.
4. Mercado N, Boersma E, Wijns E et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001; 38: 645-52.
5. Hausleiter J, Kastrati A, Mehilli J et al. Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol 2002; 40: 882-9.
6. Babapulle MN, Joseph L, Belisle P et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-91.
7. Katritsis DG, Karvouni E, Ioannidis JP. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 2005; 95: 640-3.
8. Lemos PA, Serruys PW, van Domburg RT et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the real world. The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190-5.
9. Reiben JHC, Serreys PW, eds. Quantitative Coronary Angiography. Developments in Cardiovascular Medicine. Dordrecht, The Netherlands: Kluwer Academic, 1991.
10. Lemos PA, Hoye A, Goedhart D et al. Clinical, angiographic and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients. Circulation 2004; 109: 1366-70.
11. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Eng J Med 2003; 349: 1315-23.
12. Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-9.
13. Stone GW, Ellis EG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting Taxus stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-7.
14. Ong AT, Serruys PW, Aoki J et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population. One year results of the Taxus-stent evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005; 45: 1135-41.
15. Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-11.
16. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J Med 2003; 346: 1773-80.
17. Regar E, Serruys PW, Bode C et al. Angiographic findings of the multicenter randomised study with the sirolimus-eluting Bx Velocity balloon-expandable stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002; 106: 1949-56.
18. Lemos PA, Mercado N, van Domburg RT et al. Comparison of late loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation 2004; 110: 3199-3205.
19. West NE, Ruygrok PN, Disco CM et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109: 867-73.
20. Morino Y, Honda Y, Okura H et al. An optimal diagnostic threshold for minimal stent area to predict target lesion revascularization following stent implantation in native coronary lesions. Am J Cardiol 2001; 88: 301-3.